Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study

A. Cuneo, G. Follows, G.M. Rigolin, A. Piciocchi, A. Tedeschi, L. Trentin, A.M. Perez, M. Coscia, L. Laurenti, G. Musuraca, L. Farina, A.R. Delgado, E.M. Orlandi, P. Galieni, F.R. Mauro, C. Visco, A. Amendola, A. Billio, R. Marasca, A. ChiarenzaV. Meneghini, F. Ilariucci, M. Marchetti, S. Molica, F. Re, G. Gaidano, M. Gonzalez, F. Forconi, S. Ciolli, A. Cortelezzi, M. Montillo, L. Smolej, A. Schuh, T.A. Eyre, B. Kennedy, K.M. Bowles, M. Vignetti, J. De La Serna, C. Moreno, R. Foà, P. Ghia, GIMEMA Party, European Research Initiative on CLL (ERIC), UK CLL forum

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1209-1217
Number of pages9
Issue number7
Publication statusPublished - 2018


  • bendamustine
  • chlorambucil
  • fludarabine
  • ibrutinib
  • rituximab, adult
  • aged
  • anemia
  • Article
  • autoimmune hemolytic anemia
  • cancer chemotherapy
  • cancer staging
  • chronic lymphatic leukemia
  • comorbidity
  • creatinine clearance
  • cytopenia
  • drug efficacy
  • drug safety
  • encephalitis
  • febrile neutropenia
  • female
  • human
  • lung infection
  • major clinical study
  • male
  • neutropenia
  • observational study
  • overall survival
  • progression free survival
  • rash
  • salvage therapy
  • thrombocytopenia
  • very elderly

Cite this